Home > Healthcare > Pharmaceuticals > Vaccines > Hepatitis B Vaccine Market

Hepatitis B Vaccine Market Trends

Report ID: GMI5826
Published Date: May 2023
Report Format: PDF

Download Free Sample

Hepatitis B Vaccine Market Trends

Rising government initiatives, policies and awareness programs have played a significant role in promoting hepatitis B vaccination. Increasing number of hepatitis B infections and deaths has significantly highlighted the importance of preventing hepatitis B infection and its associated health burdens. Various governments have implemented numerous strategies to increase vaccine coverage including mandating hepatitis B vaccination for infants, children, and high-risk populations. Integrating the vaccine into routine immunization schedules and providing financial support for vaccination programs is expected to boost the market share.

For instance, in 2018, according to the Ministry of Health and Family Welfare, Government of India has launched National Viral Hepatitis Control Program. This program is aimed to control and manage hepatitis B and hepatitis C infections. Thus, such government initiatives and awareness programs is anticipated to foster the industry outlook.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for hepatitis B vaccine generated USD 3.3 billion in 2022 and is estimated to grow at 5.1% CAGR and amass USD 5.7 billion by 2032 driven by the high prevalence of chronic infection, liver cirrhosis, and liver cancer.

The combination vaccine segment accounted for over 65% market share in 2022 and is projected to witness robust growth over 2023-2032 owing to their increasing use to provide protection against multiple diseases in a single shot.

The North America hepatitis B vaccine industry held over 40.6% revenue share in 2022 and is set to grow at a considerable rate through 2032 attributed to the high prevalence of hepatitis B infections, coupled with the increasing population at risk, including newborns and healthcare workers.

The top firms operating in the hepatitis B vaccine industry are Merck & Co., Inc, Sanofi S.A., GlaxoSmithKline plc., and Dynavax Technologies Corporation, among others.